Skip to main content
Top
Gepubliceerd in:

26-04-2017 | Brief Report

Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder

Auteurs: Logan K. Wink, Ryan Adams, Ernest V. Pedapati, Kelli C. Dominick, Emma Fox, Catherine Buck, Craig A. Erickson

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 7/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
go back to reference Klein, D. J., Cottingham, E. M., Sorter, M., Barton, B. A., & Morrison, J. A. (2006). A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. The American Journal of Psychiatry, 163, 2072–2079. doi:10.1176/ajp.2006.163.12.2072.CrossRefPubMed Klein, D. J., Cottingham, E. M., Sorter, M., Barton, B. A., & Morrison, J. A. (2006). A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. The American Journal of Psychiatry, 163, 2072–2079. doi:10.​1176/​ajp.​2006.​163.​12.​2072.CrossRefPubMed
go back to reference Maayan, L., & Correll, C. U. (2011). Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21, 517–535. doi:10.1089/cap.2011.0015.CrossRefPubMed Maayan, L., & Correll, C. U. (2011). Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21, 517–535. doi:10.​1089/​cap.​2011.​0015.CrossRefPubMed
go back to reference Martin, A., et al. (2004). Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. The American Journal of Psychiatry, 161, 1125–1127.CrossRefPubMed Martin, A., et al. (2004). Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. The American Journal of Psychiatry, 161, 1125–1127.CrossRefPubMed
go back to reference McCracken, J. T., et al. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321.CrossRefPubMed McCracken, J. T., et al. (2002). Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347, 314–321.CrossRefPubMed
go back to reference Owen, R., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540.CrossRefPubMed Owen, R., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540.CrossRefPubMed
go back to reference Park, S. Y., et al. (2016). Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55(456–468), e4. doi:10.1016/j.jaac.2016.03.012. Park, S. Y., et al. (2016). Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55(456–468), e4. doi:10.​1016/​j.​jaac.​2016.​03.​012.
go back to reference Schubart, J. R., Camacho, F., & Leslie, D. (2014). Psychotropic medication trends among chidren and adolescents with autism psectrum disorder in the Medicaid program. Autism, 18, 631–637.CrossRefPubMed Schubart, J. R., Camacho, F., & Leslie, D. (2014). Psychotropic medication trends among chidren and adolescents with autism psectrum disorder in the Medicaid program. Autism, 18, 631–637.CrossRefPubMed
go back to reference Yoon, Y., Wink, L. K., Pedapati, E. V., Horn, P. S., & Erickson, C. A. (2016). Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology. doi:10.1089/cap.2016.0049.PubMed Yoon, Y., Wink, L. K., Pedapati, E. V., Horn, P. S., & Erickson, C. A. (2016). Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology. doi:10.​1089/​cap.​2016.​0049.PubMed
Metagegevens
Titel
Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder
Auteurs
Logan K. Wink
Ryan Adams
Ernest V. Pedapati
Kelli C. Dominick
Emma Fox
Catherine Buck
Craig A. Erickson
Publicatiedatum
26-04-2017
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 7/2017
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-017-3132-2

Andere artikelen Uitgave 7/2017

Journal of Autism and Developmental Disorders 7/2017 Naar de uitgave